Roche Holding stock edges higher after solid half year 2026 results
Published on 08/13/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding AG (ISIN CH0012032048) stock is trading near recent highs as the Swiss healthcare group reports a 6% sales increase at constant exchange rates in the first half of 2026, underlining steady momentum in its pharmaceuticals and diagnostics businesses as of August 13, 2026.
Half year 2026 results show 6% sales growth
According to Roche's half year 2026 results, group sales for the first six months of 2026 reached CHF 30.4 billion, representing a 6% increase at constant exchange rates compared with the prior year period.
The company highlighted that this growth was supported by contributions from both its pharmaceuticals division and diagnostics portfolio, with management pointing to 'strong momentum' and positive developments across its pipeline of new therapies and testing solutions in the report dated August 13, 2026.
Stock performance and US market context
On the US over-the-counter market, Roche's American depositary receipts (ADR) under the ticker RHHBY were quoted at $56.51 as of August 12, 2026, 3:59 p.m. Eastern Time, with the price down $0.11 or 0.19% on the day according to data compiled by MarketBeat.
The same overview notes that RHHBY opened 2026 at $51.57 and has since gained 9.6%, trading at $56.51 by mid-August 2026, which places the current level noticeably above the start-of-year price and confirms a year-to-date advance of nearly 10% for Roche Holding stock.
In the Swiss home market, a quote snapshot for Roche Holding participation shares shows a recent price of CHF 366.60 with an intraday range from CHF 366.10 to CHF 370.60 and an opening price of CHF 369.20, illustrating that the shares continue to trade in the upper part of their recent range as of the latest session referenced on August 12, 2026 via Investing.com price data.
More context on Roche Holding stock
Read additional news and background on Roche Holding stock and how the company's latest financial results and pipeline developments fit into the broader healthcare sector.
Representative product: oncology therapies
Within its pharmaceuticals division, Roche is widely recognized for its oncology medicines, which remain a core driver of sales and a key area of ongoing research and development, supporting the company's long-term growth prospects as highlighted broadly in its corporate communications.
Roche Holding stock and current market value
As of August 12, 2026, RHHBY ADRs trade on the US OTC market at $56.51, with Roche Holding's equity valuation referenced around $331 billion in a recent overview that lists the group among large global healthcare companies.
Roche Holding stock snapshot
- Company: Roche Holding AG
- ISIN: CH0012032048
- Ticker: RHHBY (ADR), ROG (Swiss listing)
- Exchange: OTC (US ADR), SIX Swiss Exchange (primary listing)
- Price (as of August 12, 2026, 3:59 p.m. ET): $56.51 USD (RHHBY ADR)
- Market cap: $331 billion (as referenced in recent data)
- Sector / Industry: Health Care - Pharmaceuticals & Biotechnology
- Index membership: Included in major Swiss and global healthcare indices
- Next earnings date: not yet officially scheduled
